Lixte Biotechnology Holdings Inc., a clinical stage pharmaceutical company, has announced that new clinical findings have been published in the scientific journal Nature, validating its ongoing trials for Ovarian and Colorectal cancers using the proprietary compound LB100. The study, led by Dr. Amir Jazaeri at MD Anderson Cancer Center, revealed that inactivating mutations in PPP2R1A are linked to improved survival outcomes for patients treated with immune checkpoint blockade therapy. These mutations enhance the interferon gamma response pathway, correlating with improved immune checkpoint responses. Lixte is currently conducting trials in collaboration with GSK and Roche to test LB100 in combination with immunotherapies for ovarian and colon cancer patients. The company anticipates releasing the first results from these clinical studies in the latter half of this year.